A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers.

Study Overview
=================
Brief Summary
-----------------
This Phase II study will evaluate the safety and efficacy of three fluoroquinolone ophthalmic agents to determine the optimal treatment in patients with infectious corneal ulcers.

Detailed Description
-----------------
This is a prospective, single masked, comparative, mono-therapeutic trial evaluating three fluoroquinolone agents that are approved and marketed for the treatment of conjunctivitis. Approximately 120 patients who have corneal ulcers greater than 2 mm but less than 6 mm in size who meet all other inclusion criteria will be enrolled into this study. Patients will be randomized in a 2:1:1 ratio to receive besifloxacin 0.6% ophthalmic suspension, gatifloxacin 0.5% ophthalmic solution, or moxifloxacin 0.5% ophthalmic solution.

Official Title
-----------------
A Single-site, Single Masked, Prospective Comparison of Three Fluoroquinolone Topical Therapies (Besifloxacin 0.6% or Gatifloxacin 0.5% or Moxifloxacin 0.5%) in the Treatment of Infectious Corneal Ulcers.

Conditions
-----------------
Corneal Ulcers

Intervention / Treatment
-----------------
* Drug: Besivance 0.6% Ophthalmic Suspension
* Drug: Zymaxid 0.5% Ophthalmic Solution
* Drug: Vigamox 0.5% Ophthalmic Solution


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients must be between the ages of 18-90 years of age. Patients must be able to understand the nature of this study, give written informed consent prior to study entry, and comply with study requirements. Patients must have a corneal ulcer greater than 2mm but less than 6mm in size. Patients must have corneal ulcer present in only one eye. Patients must agree not to wear contact lenses while on study. Exclusion Criteria: Patients with multifocal ulcers. Signs of any other viral or fungal infection. Treatment with antibiotics within 14 days of study entry. Treatment with systemic or topical ocular antiviral agents or systemic or topical steroids or topical ocular nonsteroidal anti-inflammatory drugs (NSAIDS) during the prior 14-day period. Known hypersensitivity or allergy to steroids (Loteprednol etabonate) or to any of the ingredients in the three study drugs (Besifloxacin 0.6% or Gatifloxacin 0.5% or Moxifloxacin 0.5%). Contact lens only with no spectacles available. Ocular surgery (including laser surgery) in either eye within 6 weeks prior to entry into this study. Participation in any investigational study within the past 30 days. Pregnant women, minors, or those not able to consent for themselves.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Besivance 0.6% Ophthalmic Suspension<br>A topical fluoroquinolone antimicrobial indicated for the treatment of bacterial conjunctivitis. | Drug: Besivance 0.6% Ophthalmic Suspension<br>* Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.<br>* Other names: Besifloxacin 0.6% Ophthalmic Suspension;|
| Active Comparator: Zymaxid 0.5% Ophthalmic Solution<br>A topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis. | Drug: Zymaxid 0.5% Ophthalmic Solution<br>* Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.<br>* Other names: Gatifloxacin 0.5% Ophthalmic Solution;|
| Active Comparator: Vigamox 0.5% Ophthalmic Solution<br>A topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis. | Drug: Vigamox 0.5% Ophthalmic Solution<br>* Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.<br>* Other names: Moxifloxacin Hydrochloride 0.5% Ophthalmic Solution;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complete Healing | The primary outcome will be complete healing of the corneal ulcer, defined as complete reepithelialization by Day 29. | 29 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Healing Rate | Time to corneal ulcer reduction and/or total healing over a treatment course of 21 days. | 29 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
infectious corneal ulcers